拉米夫定联合猪苓多糖治疗慢性乙型肝炎的疗效分析

Analysis of curative effect of lamivudine combined with zhulingduotang on patient with chronic hepatitis B

目的 观察拉米夫定联合猪苓多糖治疗慢性乙型肝炎的近期疗效及安全性。方法 将 78例慢性乙型肝炎患者随机分为拉米夫定 (10 0 m g/ d)联合猪苓多糖 (2 0 m g/ d)治疗为治疗组 ;单独服用拉米夫定 (10 0 mg/d)为对照组 ,6个月为 1疗程 ,疗程结束后继续随访 1年。结果 治疗组与对照组在 8周时 HBe Ag阴转 ,HBV- DNA阴转率差异不显著 (P>0 .0 5 ) ,而在 2 4周、4 0周时差异有显著性 (P<0 .0 5 )。结论 拉米夫定虽然快速抑制 HBV-DNA复制 ,但不能彻底清除肝内外 ccc DNA,联合免疫调节剂 ,如猪苓多糖可提高 HBe Ag阴转率及 HBV- DNA阴转率 ,降低耐药性 。

Objective To observe the recent curative effect and safety of lmivudine with zhulingduotang on patients with chronic hepatitis B.Methods Seventy eight patients were divided into two groups randomly.Treated group taken lmivudine and zhulingduotang for 6 months and the control group was given lmivudine alone.The patients were followed up for 1 year after treatment.Results After 8 weeks,the HBeAg in the two groups all turned to negative while the HBV DNA in the two groups turned to negative unmarkedly.But after 24 weeks and 40 weeks,the difference is significant.Conclusion Lamivudine can restrain the duplication of HBV DNA quickly,but can't get rid of the cccDNA inside and outside of the liver throughly.Lamivudine combined with immunity regulator such as zhulingduotang can raise the rate of negatication of HBeAg and HBV DNA decrease the drug resistance and shortened the course of treatment by using lamivudine in treating chronic hepatitis B.